Allergan Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Allergan Plc (AGN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Allergan Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 16,096M vs 1,862M combined for tracked competitors (89.6% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-10.4% annualized vs trailing 12 months), vs decelerating (-16.4%) for its tracked peer group.
- Growth: Allergan Plc generated 0.2% revenue growth year over year in Q1 2020, vs -2.1% for its tracked competitors combined.
- Profitability: Its 10.5% net margin compares with -8.2% for the peer group.
- Peer revenue share: Allergan Plc accounted for 90.3% of combined revenue among its tracked peer group, up from 90.1% a year earlier.
- Peer differentiation: Revenue per employee of $1.53M compares with $0.40M for the peer group (3.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AGN Sales vs. its Competitors, Q1 2020
Allergan Plc reported revenue growth of 0.20 % year on year in Q1 2020, above its competitors' combined revenue change of -2.12 %.
With a net margin of 10.51 %, Allergan Plc achieved higher profitability than its competitors (-8.20 %).
Allergan Plc generated 90.25 % of the combined sales of its peer group, up from 90.05 % a year earlier.
Allergan Plc vs. its Competitors, Q1 2020
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Allergan Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Allergan plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (16) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Allergan Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 0.2% for Allergan Plc. Allergan Plc's share of combined industry revenue moved from 0.76% to 0.70%, a loss of 0.06 percentage points.
Allergan Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Allergan plc | No | Yes | No | No |
| Competitors combined (7) | ||||
| High-Confidence Competitors (20) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) | 16.70 % (1 of 6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AGN Stock Performance relative to its Competitors
AGN Stock Performance relative to High-Confidence Competitors
AGN Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Electrocore Inc | 282.9% | Outperformed |
| 2 | Integra Lifesciences Holdings Corp | 282.9% | Outperformed |
| 3 | Stablecoin Development Corporation | 282.9% | Outperformed |
| 4 | Evofem Biosciences Inc | 282.9% | Outperformed |
| 5 | Waldencast Plc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Allergan Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Allergan plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Allergan plc | 64,063.34 | 16,096.20 |
| Integra Lifesciences Holdings Corp | 991.17 | 1,647.67 |
| Stablecoin Development Corporation | 235.81 | 5.63 |
| Waldencast Plc | 100.31 | 272.02 |
| Electrocore Inc | 95.36 | 36.53 |
| Cutera Inc | 1.95 | 154.20 |
| SUBTOTAL | 65,490.71 | 18,232.86 |
Sign in to see all competitors of Allergan plc.
Sources: Allergan plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Allergan plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Allergan Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Integra Lifesciences Holdings Corp | Named by the company | 85% |
| Pmgc Holdings Inc | Named by the company | 85% |
| Cutera Inc | Named by the company | 85% |
| Agile Therapeutics Inc | Named by the company | 85% |
| ENTO | Named by the company | 85% |
| Gridai Technologies Corp | Named by the company | 85% |
| Kalvista Pharmaceuticals Inc | Named by the company | 85% |
| ACOR | Named by the company | 85% |
| Bright Minds Biosciences Inc | Named by the company | 85% |
| Eyepoint Inc | Named by the company | 85% |
| Intra cellular Therapies Inc | Named by the company | 85% |
| Spyglass Pharma Inc | Named by the company | 85% |
| Alimera Sciences Inc | Named by the company | 85% |
| Evolus Inc | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
| Acorda Therapeutics Inc | Named by the company | 85% |
| Greenwich Lifesciences Inc | Named by the company | 85% |
| Jaguar Health Inc | Named by the company | 85% |
| Tela Bio Inc | Named by the company | 85% |
| Atlantic Coastal Acquisition Corp Ii | Named by the company | 85% |
| Establishment Labs Holdings Inc | Named by the company | 85% |
| Opus Genetics Inc | Named by the company | 85% |
| OCUP | Named by the company | 85% |
| Electrocore Inc | Named by the company | 85% |
| Waldencast Plc | Named by the company | 85% |
| Evofem Biosciences Inc | Named by the company | 85% |
| Stablecoin Development Corporation | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Allergan Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Allergan Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Allergan plc | US Specialized Therapeutics 42.77 % |
| Integra Lifesciences Holdings Corp | Specialty Surgery 73.85 % |
| Waldencast Plc | Obagi Skincare 59.42 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Allergan Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Allergan plc | 64,063 | 1,532,971 | -236,076 |
| Integra Lifesciences Holdings Corp | 991 | 372,186 | -1,636 |
| Stablecoin Development Corporation | 236 | - | - |
| Waldencast Plc | 100 | 747,302 | -681,473 |
| Electrocore Inc | 95 | 440,084 | -177,952 |
| Cutera Inc | 2 | 358,600 | -334,209 |
| PEERS TOTAL | 1,427 | 398,111 | 7,621 |
Allergan Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Integra Lifesciences Holdings Corp | United States 73.34 % |
| Cutera Inc | Rest of World 21.40 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Allergan Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (345 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 83.73 % | 63.89 % (avg) | +19.8 pp |
| Operating Margin | -21.34 % | industry median | +127.8 pp |
| EBITDA Margin | 14.62 % | -7.15 % (avg) | +21.8 pp |
| Capital Intensity (Capex / Revenue) | 2.98 % | 4.87 % (avg) | -1.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Allergan Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (345 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 24.9x | - |
| EV / EBITDA | 33.9x | 17.1x | +16.8x |
| P/B | 1.1x | 4.5x | -3.4x |
| Return on Equity | -4.23 % | industry aggregate | -16.46 % |
| Return on Invested Capital | -1.72 % | -2.89 % (avg) | 1.17 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Allergan Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2009 | 2011 | 2012 | 2013 | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 2.28 % | 10.16 % | 7.14 % | 27.37 % | -14.20 % | 9.40 % | -0.96 % | 1.91 % |
| Operating Margin | 20.61 % | 25.19 % | 27.79 % | 24.47 % | -12.53 % | -37.15 % | -39.57 % | -27.63 % |
| Return on Invested Capital | 8.55 % | 11.16 % | 12.02 % | 12.34 % | -0.65 % | -2.21 % | -2.54 % | -2.19 % |
| P/E | 29.6x | 28.3x | 26.7x | 28.8x | 5.4x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Allergan Plc's Strategic Group Map
Every company in Allergan Plc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Allergan Plc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Allergan Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.98 % vs industry average 4.87 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Allergan Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Allergan Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Allergan Plc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Allergan Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Allergan Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 127.8 points above the industry median.
Weaknesses
- Return on equity 16.5 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-10.4% annualized vs trailing 12 months).
Opportunities
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-16.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Allergan Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Allergan plc | 0.18 | 1.01 | 0.37 |
| Integra Lifesciences Holdings Corp | 0.61 | 3.12 | 1.87 |
| Stablecoin Development Corporation | 5.56 | 6.02 | - |
| Waldencast Plc | 0.41 | 1.70 | 0.25 |
| Electrocore Inc | 0.63 | 1.26 | - |
| Cutera Inc | 1.41 | 3.17 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Allergan Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Allergan plc | Q1 2020 | +0.2 % | - |
| Integra Lifesciences Holdings Corp | Q2 2026 | +0.8 % | - |
| Stablecoin Development Corporation | Q2 2026 | - | - |
| Waldencast Plc | Q4 2025 | -0.6 % | - |
| Electrocore Inc | Q2 2026 | +28.0 % | - |
| Cutera Inc | Q3 2024 | -31.5 % | - |
| PEERS TOTAL | -0.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Allergan Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Allergan plc | Q1 2020 | +25.2 % | +63.2 % |
| Integra Lifesciences Holdings Corp | Q2 2026 | -3.5 % | -38.9 % |
| Stablecoin Development Corporation | Q2 2026 | - | - |
| Waldencast Plc | Q4 2025 | +8.4 % | -22.0 % |
| Electrocore Inc | Q2 2026 | +35.6 % | -84.0 % |
| Cutera Inc | Q3 2024 | -25.0 % | -96.9 % |
Allergan Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Allergan plc | - | - | - |
| Integra Lifesciences Holdings Corp | - | - | - |
| Stablecoin Development Corporation | 604.72% | 618.18% | - |
| Waldencast Plc | - | - | - |
| Electrocore Inc | - | - | - |
| Cutera Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Allergan Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Allergan plc | - | 3.98 |
| Integra Lifesciences Holdings Corp | - | 0.60 |
| Stablecoin Development Corporation | - | 41.91 |
| Waldencast Plc | - | 0.37 |
| Electrocore Inc | - | 2.61 |
| Cutera Inc | - | 0.01 |
| PEERS AVERAGE | - | 3.59 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.